This supports that combination targeting of the Rho-GTPases and M2 macrophage activation (e.g., CSF1R inhibition) would be an effective strategy to suppress breast cancer cell invasion for use for example in the adjuvant setting in high-risk lesions or in combination with other chemo or immune therapies, which elicit cancer cell death. This evidence concerns the gene CSF1R and cancer.